Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00611585 · ClinicalTrials.gov registry record · NA

A Safety and Efficacy Study of the Birmingham Hip Resurfacing System

A NA study of Arthritis, sponsored by Smith & Nephew.

Completed
Registry status
NA
Development phase
360
Enrollment target
7
Study locations

NCT00611585 is a NA study of Arthritis that has completed, run by Smith & Nephew. The registered enrollment target is 360 participants, below the 4,503-participant average among 48 other Arthritis trials with a reported enrollment target (92% lower). The trial reports 7 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00611585, a NA study of Arthritis, has completed, sponsored by Smith & Nephew.

COMPLETED
Registry status
NA
Development phase
360 participants
Enrollment target
7
Study locations

Study Summary

The purpose of this study is to meet a PMA condition of approval of the BHR System. The study will evaluate the long term safety and effectiveness of the BHR system in patients with non-inflammatory and inflammatory arthritis.

Conditions Studied

Interventions

  • DEVICE Birmingham Hip Resurfacing

Study Locations (7)

New York

  • Hospital for Special Surgery - New York
  • University of Rochester Medical Center - Rochester

Arizona

  • Tucson Orthopaedic Institute - Tucson

Louisiana

  • Center for Orthopaedics - Lake Charles

North Carolina

  • OrthoCarolina - Charlotte

Virginia

  • Anderson Orthopaedic Clinic - Alexandria

Wisconsin

  • Aurora Medical Center - Grafton

Trial Details

FieldValue
Enrollment Target 360 participants
Start Date 2006-09
Est. Completion 2025-05-12
Phase NA

Sponsor

Smith & Nephew

72 total trials

What the Registry Record Tells You About NCT00611585

The ClinicalTrials.gov registry entry for NCT00611585 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,503-participant average among 48 other Arthritis trials with a reported enrollment target (92% lower). The listed sponsor is Smith & Nephew, which has 72 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Birmingham Hip Resurfacing is the first listed.

NCT00611585 reports 7 study locations spanning 6 distinct geographic areas - top geographies include New York, Arizona, Louisiana.

Frequently Asked Questions

What is clinical trial NCT00611585 about?

NCT00611585 is a clinical study titled "A Safety and Efficacy Study of the Birmingham Hip Resurfacing System". The purpose of this study is to meet a PMA condition of approval of the BHR System. The study will evaluate the long term safety and effectiveness of the BHR system in patients with non-inflammatory and inflammatory arthritis.

What is the current status of trial NCT00611585?

This trial is currently completed. It is a NA study. The enrollment target is 360 participants. The study started on 2006-09. Estimated completion is 2025-05-12.

What conditions does trial NCT00611585 study?

This clinical trial studies the following conditions: Arthritis.

What interventions are being tested in trial NCT00611585?

The interventions under investigation include: Birmingham Hip Resurfacing (DEVICE).

Who is sponsoring clinical trial NCT00611585?

This trial is sponsored by Smith & Nephew, which has 72 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00611585 being conducted?

This trial has 7 study locations across Arizona, Louisiana, New York, North Carolina, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.